case_images: PMC6029461_01
case_images: Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.001.jpg
case_images: PMC6029461_04_CRICC2018-1205613.001.jpg
case_images: fig1
case_images: The course of norepinephrine is shown in Figure 1.
case_images: Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.002.jpg
case_images: PMC6029461_04_CRICC2018-1205613.002.jpg
case_images: fig2
case_images: The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
case_images: PMC6029461_02
case_images: Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.001.jpg
case_images: PMC6029461_04_CRICC2018-1205613.001.jpg
case_images: fig1
case_images: The course of norepinephrine is shown in Figure 1.
case_images: Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.002.jpg
case_images: PMC6029461_04_CRICC2018-1205613.002.jpg
case_images: fig2
case_images: The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
case_images: PMC6029461_03
case_images: Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.001.jpg
case_images: PMC6029461_04_CRICC2018-1205613.001.jpg
case_images: fig1
case_images: The course of norepinephrine is shown in Figure 1.
case_images: Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.002.jpg
case_images: PMC6029461_04_CRICC2018-1205613.002.jpg
case_images: fig2
case_images: The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
case_images: PMC6029461_04
case_images: Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.001.jpg
case_images: PMC6029461_04_CRICC2018-1205613.001.jpg
case_images: fig1
case_images: The course of norepinephrine is shown in Figure 1.
case_images: Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
case_images: CRICC2018-1205613.002.jpg
case_images: PMC6029461_04_CRICC2018-1205613.002.jpg
case_images: fig2
case_images: The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
case_images: Course of IL-6 during Cytosorb treatment in Case 5. Values are shown after the first Cytosorb treatment, and then after every 24h until the end.
case_images: CRICC2018-1205613.003.jpg
case_images: PMC6029461_04_CRICC2018-1205613.003.jpg
case_images: fig3
case_images: Moreover, the inflammatory status was also monitored during Cytosorb treatment dosing IL-6 levels (Figure 3), directly adsorbed by the sorbent.